Showing 7331-7340 of 21432 results for "".
- Drug Enhances Radiation Efficacy for Lung Cancer Patients with Brain Metastaseshttps://reachmd.com/news/drug-boosts-radiation-for-metastatic-lung-cancer/2468376/Researchers from the University of Cincinnati have discovered a promising approach to improve radiation treatment for patients with metastatic lung cancer, potentially offering better outcomes for those battling this aggressive form of the disease. The study, led by Debanjan Bhattacharya, PhD, an
- Collagen for Anti-Aging: Does It Really Work?https://reachmd.com/news/does-collagen-really-help-fight-wrinkles-and-aging-dermatologist-explains/2468363/The promise of youthful, wrinkle-free skin often leads consumers to seek out collagen products, but do these over-the-counter supplements and creams actually deliver results? Collagen, a key protein that gives skin its elasticity and firmness, naturally declines with age, contributing to wrinkles
- LEO Pharma’s Phase 2a Trial Shows Promising Results for New Atopic Dermatitis Treatmenthttps://reachmd.com/news/leo-pharma-presents-late-breaking-results-from-the-phase-2a-mechanism-of-action-trial-of-temtokibart-and-dupilumab-in-moderate-to-severe-atopic-dermatitis-at-the-2024-eadv-annual-meeting/2468337/LEO Pharma has announced encouraging findings from its Phase 2a Mechanism of Action (MoA) trial, showcasing
- Study Links COVID-19 to Time-Dependent Risks of Acute Kidney Disordershttps://reachmd.com/news/covid-19-linked-to-increased-risk-of-acute-kidney-disorders-study-reveals-time-varying-effects/2468362/A recent study from West China Hospital, Sichuan University, has found that COVID-19 is associated with a fluctuating risk of acute kidney disorders (AKD), including acute kidney injury (AKI). Published in Health Data Science, the
- Oruka Therapeutics Presents Preclinical Data for ORKA-001 at EADV Congresshttps://reachmd.com/news/oruka-therapeutics-announces-preclinical-data-for-orka-001-at-the-european-academy-of-dermatology-and-venereology-congress/2468338/Extended Half-Life of ORKA-001 Suggests Potential for Infrequent Dosing in Plaque Psoriasis Treatment Oruka Therapeutics has announced new preclinical data
- A Breakthrough in Treating Male Postpartum Depression: New Study Sheds Lighthttps://reachmd.com/news/new-camh-led-study-highlights-effective-treatment-for-male-postpartum-depression/2468355/A groundbreaking study led by the Centre for Addiction and Mental Health (CAMH) and researchers in Pakistan has revealed an effective psychosocial inte
- Experts Call for Nutrition Education Overhaul in U.S. Medical Schoolshttps://reachmd.com/news/expert-panel-calls-for-nutrition-competencies-in-us-medical-education/2468358/A panel of experts in nutrition and medicine is urging the integration of nutrition competencies into U.S. medical education to address the growing prevalence of
- Opioid Prescriptions for US Patients Undergoing Long-Term Dialysis or with Kidney Transplant from 2011 to 2020https://reachmd.com/news/opioid-prescriptions-for-us-patients-undergoing-long-term-dialysis-or-with-kidney-transplant-from-2011-to-2020/2468345/Background: Pain is important for patients with kidney failure, but opioid medication prescriptions are associated with morbidity and mortality. The Centers for Disease Control an
- Teclistamab Shows Potential in Treating Severe Lupushttps://reachmd.com/news/severe-lupus-undetectable-in-patient-after-treatment-with-cancer-medication/2468348/A case study from Charité – Universitätsmedizin Berlin has demonstrated that the cancer medication teclistamab induced full remission in a 23-year-old female patient suffering from severe systemic lupus erythematosus (SLE). This case suggests that teclistamab, typically used for multiple myeloma,
- Post-hoc Analysis of Upadacitinib Phase 3 Trials Shows Positive Results for Atopic Dermatitishttps://reachmd.com/news/abbvie-upadacitinib-phase-3-trials-post-hoc-analysis-show-positive-results-in-atopic-dermatitis/2468336/A recent post-hoc analysis of AbbVie's Phase 3 trials has revealed promising outcomes for patients with moderate-to-severe atopic dermatitis (AD), particularly in those with head and neck involvement. The results underscore the efficacy of RINVOQ (upadacitinib), a Janus kinase (JAK) inhibitor, in